Policy Statement

Bronchial thermoplasty for the treatment of asthma is considered investigational.

Policy Guidelines

Coding

The following Category I CPT codes are specific for this procedure:

- 31660: Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe
- 31661: Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes

Description

Bronchial thermoplasty is a potential treatment option for patients with severe persistent asthma. It consists of radiofrequency energy delivered to the distal airways with the aim of decreasing smooth muscle mass believed to be associated with airway inflammation.

Related Policies

- N/A

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

In April 2010, the Alair® Bronchial Thermoplasty System (Asthmatx, now Boston Scientific) was approved by the U.S. Food and Drug Administration through the premarket approval process (P080032) for use in adults with severe and persistent asthma whose symptoms are not adequately controlled with low-dose ICS and LABA. Use of the treatment is contraindicated in patients with implantable devices and those with sensitivities to lidocaine, atropine, or benzodiazepines. It should also not be used while patients are experiencing an asthma exacerbation, active respiratory infection, bleeding disorder, or within two weeks of making changes in their corticosteroid regimen. The same area of the lung should not be treated more than once with bronchial thermoplasty. Food and Drug Administration product code: OOY.
Rationale

Background
Asthma
Asthma, a chronic lung disease, affects approximately 8.3% of adults and 8.3% of children in the U. S. and, in 2017, accounted for approximately 1.7 million emergency department visits and 3615 deaths. Asthma symptoms include episodic shortness of breath that is generally associated with other symptoms such as wheezing, coughing, and chest tightness. Objective clinical features include bronchial hyperresponsiveness, airway inflammation, and reversible airflow obstruction (at least 12% improvement in forced expiratory volume in 1-second post-bronchodilator, with a minimum of 200 mL improvement). However, there is substantial heterogeneity in the inflammatory features of patients diagnosed with asthma, and this biologic diversity is responsible, at least in part, for the variable response to treatment in the asthma population.

Management
Management of asthma consists of environmental control, patient education, management of comorbidities, and regular follow-up for affected patients, as well as a stepped approach to medication treatment. Guidelines from the National Heart, Lung and Blood Institute have defined six pharmacologic steps: step 1 for intermittent asthma and steps 2 through 6 for persistent asthma. The preferred daily medications: step 1: short-acting β-agonists as-needed; step 2: low-dose inhaled corticosteroids (ICS); step 3: ICS and long-acting β-agonists (LABA) or medium-dose ICS; step 4: medium-dose ICS and LABA; step 5: high-dose ICS and LABA; and step 6: high-dose ICS and LABA, and oral corticosteroids.

Despite this multidimensional approach, many patients continue to experience considerable morbidity. In addition to ongoing efforts to implement optimally standard approaches to asthma treatment, new therapies are being developed. One recently developed therapy is bronchial thermoplasty, the controlled delivery of radiofrequency energy to heat tissues in the distal airways. Bronchial thermoplasty is based on the premise that patients with asthma have an increased amount of smooth muscle in the airway and that contraction of this smooth muscle is a major cause of airway constriction. The thermal energy delivered via bronchial thermoplasty aims to reduce the amount of smooth muscle and thereby decrease muscle-mediated bronchoconstriction with the ultimate goal of reducing asthma-related morbidity. Bronchial thermoplasty is intended as a supplemental treatment for patients with severe persistent asthma (i.e., steps 5 and 6 in the stepwise approach to care).

Bronchial thermoplasty procedures are performed on an outpatient basis, and each session lasts approximately one hour. During the procedure, a standard flexible bronchoscope is placed through the patient's mouth or nose into the most distal targeted airway, and a catheter is inserted into the working channel of the bronchoscope. After placement, the electrode array in the top of the catheter is expanded, and radiofrequency energy is delivered from a proprietary controller and used to heat tissue to 65°C over a 5-mm area. The positioning of the catheter and application of thermal energy is repeated several times in contiguous areas along the accessible length of the airway. At the end of the treatment session, the catheter and bronchoscope are removed. A course of treatment consists of three separate procedures in different regions of the lung scheduled about three weeks apart.

Literature Review
This review was informed by a Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessment (2014). Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life (QOL), and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that...
condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

For conditions such as asthma, where there are subjective outcomes such as self-reported symptoms and frequency of as-needed medication, placebo- or sham-controlled randomized trials are needed to demonstrate that the intervention has a benefit beyond the placebo effect.

**Bronchial Thermoplasty for the Treatment of Asthma**

**Clinical Context and Test Purpose**

The purpose of bronchial thermoplasty in patients who have asthma refractory to standard treatment is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does bronchial thermoplasty improve health outcomes in patients with treatment-refractory asthma?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with treatment-refractory asthma. Asthma symptoms can vary between individuals but may include bronchial hyperresponsiveness, airway inflammation, and reversible airflow obstruction. For adults with persistent and severe asthma whose symptoms are not adequately controlled with low-dose inhaled corticosteroids and long-acting b-agonists (LABAs), bronchial thermoplasty may be an add-on treatment.

**Interventions**

The therapy being considered is bronchial thermoplasty as an add-on treatment in patients whose asthma is not adequately controlled with medical management.

Bronchial thermoplasty delivers thermal energy to tissue in the distal airways in an attempt to reduce excess smooth muscle, which causes airway constriction in active disease. Radiofrequency energy is applied through a catheter and a flexible bronchoscope. A typical full course of treatment consists of three, one-hour sessions, given three weeks apart under moderate sedation. All accessible airways distal to the main stem bronchus that are 3 to 10 mm in diameter are treated once, except those in the right middle lobe; the lower lobes are treated first followed by the upper lung.

**Comparators**

Currently, clinical response to continued medical management is being used to make decisions about the use of bronchial thermoplasty for treatment-refractory asthma. Continued medical management of asthma consists of environmental control, patient education, management of comorbidities, and regular follow-up for affected patients, as well as a stepped approach to medication treatment.
Outcomes
Beneficial outcomes are symptom relief, improvement in QOL, reductions in medication adverse events and hospitalizations, and treatment-related morbidity. Instruments such as the Asthma Quality of Life Questionnaire (AQLQ) score may be used to assess improvements in asthma symptoms.

Potential harms include periprocedural risk and risk for exacerbation of asthma during the treatment phase.

Timing
Short-term and long-term outcomes are important. Short-term results are evaluated from weeks posttreatment to 12 months. Long-term follow-up studies have evaluated patients receiving bronchial thermoplasty up to five years posttreatment.

Setting
Patients would be treated in the outpatient setting by a pulmonologist.

Randomized Controlled Trials
There are three industry-sponsored RCTs that have evaluated the efficacy and safety of bronchial thermoplasty. The study characteristics and results are summarized in Tables 1 and 2.

Research in Severe Asthma Trial
Pavord et al (2007) published the initial results of the RISA trial. Participants met multiple criteria for severe uncontrolled asthma. After a two-week run-in period, participants were randomized to a control group that received continued medical management alone or to medical management plus treatment with the Alair Bronchial Thermoplasty System.

The primary objective of RISA was to determine the safety of bronchial thermoplasty. The rates of the procedure and postprocedure respiratory adverse events as well as more serious adverse events (defined as any event that was fatal, required prolonged hospitalization, caused substantial immediate risk of death, resulted in permanent impairment, or required intervention to prevent permanent impairment). No overall statistical analysis was done that compared serious adverse events in the two groups.

Secondary objectives included an evaluation of the effect of bronchial thermoplasty on asthma symptoms and daily medication requirements as an indication of efficacy. At 52 weeks, bronchial thermoplasty patients had a significantly greater improvement in b-agonist use than control patients (decrease of 26 puffs per week vs 6 puffs per week, respectively, p < 0.05). There were no significant differences between groups in other efficacy variables including morning and evening peak expiratory flow, symptom scores, number of symptom-free days, percent predicted improvement in forced expiratory volume in 1-second (FEV1) and QOL measures. The small sample size limited the power to detect differences in the efficacy outcomes.

Pavord et al (2013) published 5-year safety data on 14 (82%) of the 17 patients randomized to bronchial thermoplasty in the RISA trial. All 14 patients completed the 3-year evaluation, and 12 patients completed evaluations at 4 and 5 years. As previously described, safety outcomes were the primary outcomes of RISA. In year one, each asthma symptom was considered an adverse event and, in subsequent years, multiple asthma symptoms were considered to be a single adverse event. Among those with follow-up data available, the number of patients with asthma adverse events in years 2, 3, 4, and 5 were 5 (36%), 7 (50%), 2 (17%), and 5 (42%), respectively. Also, during years 2 to 5, there were 11 respiratory-related hospitalizations in 5 patients. The number of patients with data available was too small to draw reliable conclusions about long-term safety, and there were no long-term data available on patients in the control group.
Asthma Intervention Research Trial
Cox et al (2007) published findings of the AIR trial, which was designed to evaluate symptom control and adverse events following bronchial thermoplasty in patients with moderate-to-severe persistent asthma. Participants were randomized to medical management with inhaled corticosteroids and LABA or to the same medical management strategy plus bronchial thermoplasty. At the end of the follow-up visits at 3, 6, and 12 months, there was a 2-week period of abstinence from LABA, during which data on exacerbations were collected. Between data collection periods, patients could use all maintenance therapies.

The primary outcome was the difference between groups in the rate of mild exacerbations from the baseline two-week abstinence period. An exacerbation was defined as the occurrence on 2 consecutive days of a reduction in the morning peak expiratory flow of at least 20% below the average value (recorded during the week before the abstinence period), the need for more than 3 additional puffs of rescue medication compared with the week before the abstinence period, or nocturnal awakening caused by asthma symptoms. The trial was powered to detect a difference between groups of eight mild exacerbations per person per year. Data were available at 3 months for 100 (89%) of 112 patients and at 12 months for 101 (90%) patients; all patients were included in the safety analysis.

The rate of adverse events was higher in the bronchial thermoplasty group during the active treatment period, but the proportion of adverse events was similar in the two groups in the posttreatment period. Posttreatment, three patients in the bronchial thermoplasty group required hospitalization and two patients in the control group required a total of three hospitalizations. A trial limitation is the lack of a sham intervention and, consequently, an inability to blind patients to the treatment group.

Thomson et al (2011) published 5-year data from the AIR trial. All trial participants who completed the 1-year follow-up visit were invited to participate in the extension study; 45 (87%) of 52 in the bronchial thermoplasty group and 24 (49%) of 49 in the control group opted to participate. Follow-up was done on an annual basis. Patients in the control group were followed for two additional years, and patients in the bronchial thermoplasty group were followed for five years. Twenty-one (88%) of 24 patients in the control group and 42 (93%) of 45 in the bronchial thermoplasty group completed the final follow-up. No instances of pneumothorax, intubation, mechanical ventilation, cardiac arrhythmias, or death were reported during the extension study. In the first year (year 2 of the study), the rate of hospitalizations was 3 (7%) of 45 in the bronchial thermoplasty group and 0 in the control group (p = 0.55). In year 3, the rate of hospitalizations in the bronchial thermoplasty group was again 3 (7%) of 45, and 1 (5%) of 21 patients in the control group (p = 0.10). Rates of emergency department visits in year 2 were 3 (7%) and 3 (12.5%) in the bronchial thermoplasty and control groups, respectively (p = 0.41); in year 3, rates were 3 (5%) and 3 (5%), respectively (p = 1.00). There was one hospitalization each of years four and five in the bronchial thermoplasty group.

In the extension study of the AIR trial, unlike the initial follow-up period, respiratory adverse events with multiple symptoms were recorded as a single adverse event. This could give a misleading impression of the total number of adverse events or relative number in the two groups. The incidence of respiratory adverse events during year 2 was 24 (53%) of 45 in the bronchial thermoplasty group and 13 (54%) of 24 in the control group. During year 3, the incidence was 24 (56%) of 43 in the bronchial thermoplasty group and 12 (57%) of 21 in the control group; differences between groups were not statistically significant in year 2 or 3. The incidence of respiratory adverse events in the bronchial thermoplasty group was similar in subsequent years; rates were 23 (53%) of 43 in year 4 and 22 (52%) of 42 in year 5.

The Thomson et al (2011) study also reported on 2 measures of lung function: post-bronchodilator FEV₁ and forced vital capacity. Exact numbers were not reported, but post-bronchodilator FEV₁ did not go below 80% of predicted in either group during years 2 to 5. The group...
comparisons of safety and efficacy in this follow-up trial were limited by the differential rate of 
follow-up between the two groups, with a lower percentage of patients in the control group 
agreeing to participate in the follow-up study.

**Asthma Intervention Research 2 Trial**
AIR2 was an RCT evaluating the efficacy of bronchial thermoplasty at 30 sites in 6 countries 
(including the U. S.); findings were published by Castro et al (2010). Unlike the other two RCTs, the 
control condition was a sham intervention, and the trial was double-blind. Eligibility criteria were 
similar to those in the AIR trial; key differences were that a higher initial dose of inhaled 
corticosteroids was required (equivalent to at least 1000 μg beclomethasone), and patients 
were required to have experienced at least 2 days of asthma symptoms during the 4-week 
baseline period and have a baseline score on the AQLQ of no more than 6.25. (The possible 
range of the AQLQ score is one to seven, with a higher number representing a better QOL.) Also 
different from the AIR trial, patients were not required to experience symptom worsening during 
a period of abstinence from LABAs. Patients were stable on their asthma medication and 
continued their regimens during the study. The primary outcome was the difference between 
groups in the change from baseline in the AQLQ score, with scores from the 6-, 9-, and 12-month 
follow-ups averaged (integrated AQLQ score). A related outcome was the proportion of 
patients who achieved a change in their AQLQ score of 0.5 or greater, generally considered the 
minimally important difference for this scale. Bayesian analysis was used. The target posterior 
probability of superiority (PPS) of bronchial thermoplasty over sham was 95%, except for the 
primary AQLQ endpoint; there the target was 96.4% to adjust for 2 interim looks at the data. The 
PPS for the analysis was not reported in the article.

Participants and outcome assessments were blinded but the intervention team was unblinded. 
The sham intervention was identical to the active treatment, except that no radiofrequency 
energy was delivered. Nine participants withdrew consent before beginning treatment, and 288 
underwent bronchoscopy and were included in the intention-to-treat population. One hundred 
eighty-five participants in the treatment group and 97 in the sham control group underwent the 
second bronchoscopy, and the same number of patients had the third bronchoscopy (it is not 
clear whether they were the same patients).

The superiority of bronchial thermoplasty was not achieved in the intention-to-treat population 
for the primary effectiveness outcome, mean change in the integrated AQLQ score. Mean 
standard deviation (SD) change was 1.35 (1.10) in the bronchial thermoplasty group and 1.16 
(1.23) in the sham control group. Using Bayesian analysis, the PPS was 96%. This did not surpass 
the target PPS of 96.4%. However, the superiority of bronchial thermoplasty on a related 
outcome was achieved. In the intention-to-treat population, the percentage of patients 
achieving an AQLQ score change of 0.5 or greater (i.e., at least the minimally important 
difference) was 79% in the bronchial thermoplasty group and 64% in the control group. The PPS 
at 99.6% surpassed the target probability for secondary outcomes of 95%. Additional analysis of 
data from the active treatment group suggested that responders (defined as a change in AQLQ 
score of at least 0.5) were more likely to have a lower baseline score than nonresponders 
(mean, 4.1 vs 5.1, respectively).

Several secondary outcomes favored bronchial thermoplasty over the sham control group. They 
included a reduction in the proportion of patients reporting asthma worsening during follow-up 
(27.3% vs 42.9%, respectively; PPS=99.7%) and a reduction in the number of emergency 
department visits (0.07 vs 0.43 visits per person per year, respectively; PPS=99.9%). Moreover, 
there was a reduction in severe exacerbations of 0.47 per person per year in the bronchial 
thermoplasty group compared with 0.70 per person per year in the control group (PPS=95.5%). 
There were no significant differences between groups in other secondary efficacy outcomes, 
including morning peak expiratory flow, the number of symptom-free days, symptom score, and 
rescue medication use.
For safety outcomes, during the treatment phase, there was a higher rate of respiratory adverse events in the active treatment group (85% of participants; mean, 1.0 events per bronchoscopy) compared with the sham group (76% of participants; mean, 0.7 events per bronchoscopy). A total of 16 (8.4%) patients in the active treatment group required 19 hospitalizations for respiratory symptoms during the treatment phase compared with 2 (2%) patients in the sham group, who required 1 hospitalization each. However, during the posttreatment period, 70% of patients in the bronchial thermoplasty group and 80% of patients in the sham group reported adverse respiratory events. During this phase of the trial, 5 (2.6%) patients in the bronchial thermoplasty group had a total of 6 hospitalizations for respiratory symptoms, and 4 (4.1%) patients in the sham group had 12 hospitalizations (1 patient had 9 hospitalizations).

In the AIR2 trial, the sham group had a relatively high response rate (e.g., 64% experienced a clinically significant increase in the AQLQ score). Blinding appeared to be initially successful and remained so for the sham group. Participants in both groups were unable to correctly guess their treatment group after the first bronchoscopy. During subsequent assessments, this continued among patients in the sham group, whereas in the bronchial thermoplasty group, a larger proportion guessed correctly.

Two- and 5-year follow-up data on patients in the treatment group of the AIR2 trial have been published. Castro et al (2011) reported on 2-year data on 166 (87%) of 190 patients randomized to the bronchial thermoplasty group. In the second year after treatment, the proportion of participants who experienced severe exacerbations was 23.0% (95% confidence interval [CI], 16.6% to 29.5%). This compares with a 30.9% (95% CI, 24.2% to 37.7%) rate of exacerbations during year 1. The proportion who experienced asthma adverse events was 28.7% (95% CI, 22.1% to 35.3%) in year 1 and 26.5% (95% CI, 19.8% to 33.2%) in year 2. Wechsler et al (2013) reported on 5-year data for 162 patients in the AIR2 trial (85% of those randomized to the treatment group). In a matched-pair analysis including the 162 study completers and the same group in previous years, the rate of severe exacerbations in years 1, 2, 3, 4, and 5 were 30.9%, 23.5%, 34.0%, 36.4%, and 21.6%, respectively. The proportion of patients experiencing severe exacerbations in years two, three, four, and five did not differ significantly from the number of exacerbations in year one. The proportion of patients who experienced asthma events (at least 3 asthma symptoms occurring at the same time) were 28.7%, 27.9%, 29.6%, 31.4%, and 24.7%, respectively. The proportion of patients with at least one hospitalization for respiratory adverse events these same years was 3.3%, 4.2%, 6.2%, 5.7%, and 1.9%, respectively. In the 12 months before bronchial thermoplasty, the rate of hospitalization for respiratory symptoms in this group was 4.2%. These follow-up studies are limited in that follow-up data were not collected on patients randomized to the sham group, and therefore outcomes (e.g., the rate of exacerbations, the rate of hospitalizations) cannot be compared in patients who did and did not receive bronchial thermoplasty.

### Table 1. Summary of Key RCT Characteristics

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
<th>Comparator</th>
</tr>
</thead>
</table>
| Pavord et al (2007) | U.K., Brazil, Canada | 8 | 2004-2006 | ≥18 y with uncontrolled asthma refractory to high-dose ICSa and LABAb | •17 medical management and BT  
•Weeks 0-6: 3 treatments at least 3 wk apart  
•Weeks 6-22: steroid stable  
•Weeks 22-36: protocol defined steroid wean  
•Weeks 36-52: investigator-led steroid reduction | •17 medical management alone  
•ICS dose tapered in 3 stages by 20% to 25% of baseline dose every 4 wk to minimal dose of fluticasone propionate 100-600 mg/d or equivalent |


<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cox et al (2007); AIR</td>
<td>U.K., Brazil, Canada, Denmark</td>
<td>11</td>
<td>2002-2005</td>
<td>18-65 y with moderate-to-severe persistent asthma requiring daily ICS&lt;sup&gt;a&lt;/sup&gt; and LABA&lt;sup&gt;b&lt;/sup&gt;</td>
<td>56 medical management and BT (3 treatments at least 3 wk apart)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; 60%-80% of predicted</td>
<td>Follow-up at 3, 6, and 12 mo&lt;sup&gt;e&lt;/sup&gt; then 2-wk LABA abstinence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Airway hyperresponsiveness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stable asthma 6 wk prior to enrollment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No current or recent respiratory infection&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 56 medical management and BT (3 treatments at least 3 wk apart)</td>
<td>56 medical management alone</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Follow-up at 3, 6, and 12 mo&lt;sup&gt;e&lt;/sup&gt; then 2-wk LABA abstinence</td>
<td>• Follow-up at 3, 6, and 12 mo&lt;sup&gt;e&lt;/sup&gt; then 2-wk LABA abstinence</td>
</tr>
<tr>
<td>Castro et al (2010); AIR2</td>
<td>U.S., EU, Canada, Australia</td>
<td>30</td>
<td>2000-2015</td>
<td>≥2 d asthma symptoms during 4-wk baseline required high initial dosage of ICS&lt;sup&gt;i&lt;/sup&gt;</td>
<td>196 received BT (3 treatments at least 3 wk apart)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Baseline AQLQ score ≤6.25</td>
<td>101 received sham procedure</td>
</tr>
</tbody>
</table>

AIR: Asthma Intervention Research Trial, AQLQ: Asthma Quality of Life Questionnaire; BT: bronchial thermoplasty, FEV<sub>1</sub>: forced expiratory volume at 1 minute, ICS: inhaled corticosteroids, LABA: long-acting β-agonist, RCT: randomized controlled trial, RISA: Research in Severe Asthma.

<sup>a</sup> Treatment of fluticasone propionate ≥750 μg/d or equivalent.
<sup>b</sup> Treatment of salmeterol ≥100 μg/d or equivalent.
<sup>c</sup> Demonstrated by challenge with methacholine or reversible bronchoconstriction during prior 12 mo.
<sup>d</sup> No more than 2 respiratory infections requiring treatment in past year and required to undergo a 2-wk baseline test period without LABAs; eligibility depended on worsening asthma control during that time.
<sup>e</sup> Between data collection periods, patients could use all maintenance therapies
<sup>f</sup> Treatment of beclomethasone ≥1000 μg or equivalent.

### Table 2. Summary of Key RCT Results

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Respiratory AE (No. of Events)</th>
<th>Serious AE (Hospitalization)&lt;sup&gt;b&lt;/sup&gt; (puffs per 7 days)&lt;sup&gt;c&lt;/sup&gt;</th>
<th>% Reduction in SABA&lt;sub&gt;c&lt;/sub&gt;</th>
<th>% Reduction in OCS Dose&lt;sup&gt;d&lt;/sup&gt;</th>
<th>% Reduction in ICS Dose&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pavord et al (2007); RISA</td>
<td>BT (n=15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>136</td>
<td>7</td>
<td>-26.6 (40.1)</td>
<td>63.6 (45.4)</td>
</tr>
<tr>
<td></td>
<td>MM (n=17)</td>
<td>57</td>
<td>0</td>
<td>-1.5 (11.7)</td>
<td>26.2 (40.7)</td>
</tr>
<tr>
<td></td>
<td>Effect (95% CI); p</td>
<td>NR (NR); &lt;0.05</td>
<td>NR (NR); 0.12</td>
<td>NR (NR); 0.059</td>
<td></td>
</tr>
<tr>
<td>Cox et al (2007); AIR</td>
<td>BT (n=52)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Baseline</td>
<td>0.35 (0.32)</td>
<td>12 months</td>
<td>0.18 (0.31)</td>
</tr>
<tr>
<td></td>
<td>Mean change</td>
<td>0.35 (0.32)</td>
<td>12 months</td>
<td>0.18 (0.31)</td>
<td>0.28 (0.31)</td>
</tr>
<tr>
<td>Castro et al (2010); AIR2</td>
<td>BT (n=190)&lt;sup&gt;g&lt;/sup&gt;</td>
<td>Baseline</td>
<td>4.30 (1.17)</td>
<td>12 months</td>
<td>5.66 (1.06)</td>
</tr>
<tr>
<td></td>
<td>Mean change</td>
<td>4.30 (1.17)</td>
<td>12 months</td>
<td>5.66 (1.06)</td>
<td>1.35 (1.10)</td>
</tr>
</tbody>
</table>

AE: adverse events; AQLQ: Asthma Quality of Life Questionnaire; BT: bronchial thermoplasty; CI: confidence interval; ICS: inhaled corticosteroid; MM: medical management; NR: not reported; OCS: oral corticosteroid; SABA: short-acting β-agonist; RCT: randomized controlled trial.

<sup>a</sup> There were 2 withdrawals from BT group prior to first treatment.
<sup>b</sup> There were no deaths or serious AEs other than hospitalization related to respiratory events in either group.
<sup>c</sup> Results at 22 wks.
<sup>d</sup> Results at 52 wks.
Change from baseline in mean number of mild exacerbations per subject per week at 12 mo.
Analyses based on participants available for evaluation at 12 mo.
Intention-to-treat analyses based on participants who underwent at least 1 bronchoscopy procedure in either arm.
Change from baseline in integrated AQLQ score at 12 months with higher score (0-7) indicating better quality of life. A score change of ≥0.5 defines minimal important difference.

**Post-Food and Drug Administration Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma**

Chupp et al (2017) compared 3-year follow-up results from 190 patients in the AIR2 trial with a subgroup (n=190) from a prospective nonrandomized clinical study (Post-Food and Drug Administration Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma [PAS2]). PAS2 is an ongoing open-label trial of the Alair system required for post-premarket approval. Of those enrolled, 168 patients from PAS2 reached 3 years of follow-up and were compared with 165 patients from AIR2 who also had 3 years of follow-up. The primary outcome was comparing the incidence of severe exacerbation in each trial. In the 12 months before treatment, 74.2% of patients from PAS2 experienced severe exacerbations, which decreased significantly during the third year of follow-up to 39.9% (p<0.001). A similar reduction was observed in AIR2 patients, with the incidence of severe exacerbations decreasing 36.8%. Similar decreases in emergency department visits occurred in both groups when year 3 was compared with the 12 months before treatment (PAS2, 55% reduction; AIR2, 72.3% reduction; p<0.001); the incidence of hospitalization also decreased for both groups. In the first and second years after treatment, the incidence of hospitalization in PAS2 decreased to 14.4% and 12.7%, respectively; the incidence of emergency department visits decreased to 18.3% in the first year and 13.5% in the second year after treatment. Overall, patients from PAS2 showed improved results comparable to those observed in AIR2; however, there were a number of differences between the trials that limited conclusions. At baseline, patients enrolled in AIR2 had better asthma control than those in PAS2; PAS2 was restricted to North America, and different definitions of severe exacerbations were used in each trial.

A TEC Assessment (2014) assessed bronchial thermoplasty as a treatment for inadequately controlled severe asthma. The Assessment included the three published RCTs discussed and concluded, “the evidence is insufficient to determine whether potential improvements in some outcomes, but not others defining the net health outcome, outweigh the potential harms” and that the technology did not meet TEC criteria.

**Observational and Nonrandomized Studies**

Several observational and nonrandomized studies were identified that provide data on safety outcomes and incidence of short-term adverse events.

Burn et al (2017) published a rigorous U.K. registry study that focused on safety outcomes. The study combined data from 2 sources, the U.K. Difficult Asthma Registry, and the Hospital Episode Statistics warehouse, and included patients treated with bronchial thermoplasty between June 2011 and January 2015. Eighty-three patients were identified in the Difficult Asthma Registry and 85 in the Hospital Episode Statistics database. For 59 patients, data in the 2 databases could be matched. Most patients had three bronchial thermoplasty treatment sessions. Data from the matched cohort were used to calculate event rates for four binary safety outcomes. Procedural complications were reported in 17 (11%) of 152 procedures in 13 (22%) patients; emergency department readmissions within 30 days of the initial hospitalization were reported for 15 (11.8%) patients; and accident and emergency visits (i.e., emergency department) for any reason were reported for 13 (8.6%) patients. For the fourth outcome (postprocedure overnight stay), 70 (46.1%) of 152 procedures were followed by an overnight stay. In total, 20.4% of procedures in the matched cohort were associated with at least 1 of the 4 safety issues. The authors noted that the relatively high rate of safety events might have been related to older patients with more severe disease being treated in clinical practice compared with patients included in clinical trials.
Langton et al (2017) published a single-center, observational study of 24 patients who had severe uncontrolled asthma and were treated with bronchial thermoplasty. The primary response was measured by change in the 5-item Asthma Control Questionnaire (ACQ-5) scores at six months after treatment. The mean ACQ-5 score of the group was 3.3 (SD=1.1) at baseline, which improved to 1.5 (SD=1.1) at six months (p<0.001). For 21 patients, the change achieved the minimal clinically significant improvement (defined as an ACQ-5 improvement ≥0.5). Authors also reported deterioration in post-bronchodilator FEV1: 24 hours after treatment, FEV1 decreased by a mean of 166 mL (95% CI, 102 to 224 mL; p<0.001). The predictors of acute change in FEV1 were age (p=0.02) and a number of activations (i.e., more activations predicted worsened FEV1 postprocedure; p=0.01). Patients deemed responders according to ACQ-5 improvement had a mean of 221 (SD=45) activations, while those clinically deemed nonresponders had a mean of 139 (SD=11) activations (p<0.01). There were significantly more activations applied to the upper lobe (78.8) than in the right (40.1) or left (42.8; p<0.001) lower lobes, which aligns with the significant deterioration in FEV1 (≥15%) in 60% of patients treated in the upper lobe (p=0.009). Patients whose right or left lower lobes were treated were quicker to return to baseline FEV1 levels by day seven postprocedure compared with those whose upper lobes were treated. While the study was limited by its small size and observational nature, it provides data on the aggravating effect radiofrequency activations may have on FEV1, especially on upper lobes.

D’Hooghe et al (2017) published results from the prospective imaging Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma trial, which assessed 12 patients who underwent 36 bronchial thermoplasty procedures and had a chest x-ray (n=34) or ultra-low-dose computed tomography (n=16). The primary outcome was radiologic abnormalities following bronchial thermoplasty, and a large percentage of the cohort showed 1 of 4 abnormalities: peribronchial consolidations and ground glass opacities (94%), atelectasis (38%), partial bronchial occlusions (63%), or bronchial dilatations (19%). There was no clear association between abnormal x-ray results and asthma exacerbation (55% experienced both) compared with the incidence of asthma exacerbations in those who had normal radiologic images (roughly 2 of every 3 patients). Seventy-three percent of abnormal results resolved within 6 weeks and 100% resolved 6 months postprocedure.

Summary of Evidence
For individuals who have asthma refractory to standard treatment who receive bronchial thermoplasty added to medical management, the evidence includes three RCTs and observational studies. The relevant outcomes are symptoms, QOL, hospitalizations, and treatment-related morbidity. Early studies (RISA, AIR) investigated safety outcomes, finding similar rates of adverse events and exacerbations between the bronchial thermoplasty and control groups. These trials were limited by their lack of sham control. The AIR2 trial is the largest of the three published RCTs, and the only one double-blinded and sham-controlled, with sites in the U. S. Over one year, bronchial thermoplasty was not found to be superior to sham treatment on the investigator-designated primary efficacy outcome of mean change in the QOL score but was found to be superior on a related outcome, improvement in the QOL of at least 0.5 points on the AQLQ. There was a high response rate in the sham group of the AIR2 trial, suggesting a large placebo effect, particularly for subjective outcomes such as QOL. There are no long-term sham-controlled efficacy data. Findings on adverse events from the three trials have suggested that bronchial thermoplasty is associated with a relatively high rate of adverse events, including hospitalizations during the treatment period, but not in the posttreatment period. Safety data up to five years have been reported in the RCTs for patients treated with bronchial thermoplasty but not for control patients. Safety data from a U.K. registry study, published in 2016, found that 20% of bronchial thermoplasty procedures were associated with a safety event (i.e., procedural complications, emergency respiratory readmissions, emergency department visits, and/or postprocedure overnight stays). Conclusions cannot be drawn about the effect of bronchial thermoplasty on the net health outcome due to the limited amount of sham-controlled data (one RCT) on short-term efficacy, the uncertain degree of treatment benefit in that single sham-controlled trial, the lack of long-term sham-controlled data in the face of a high initial placebo
response, and the presence of substantial adverse events. Also, there is a lack of data on patient selection factors for this procedure and, as a result, it is not possible to determine whether there are patient subgroups that might benefit. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests from Blue Cross Blue Shield Association, input was received from 1 physician specialty society and 4 academic medical centers in 2014. Input was mixed on whether bronchial thermoplasty is considered investigational for the treatment of asthma; three reviewers agreed with this statement and two reviewers disagreed. Reviewers who disagreed tended to use bronchial thermoplasty in patients who had not responded to other treatments and who did not think there were treatment alternatives.

Practice Guidelines and Position Statements
Global Initiative for Asthma
Global Initiative for Asthma is an international network of organizations and professionals with expertise in asthma. The group has been updating a report entitled Global Strategy for Asthma Management and Prevention annually since 2002; the most recent update was issued in 2019.15 The organization has recommended stepped care for treatment of asthma. Options for add-on treatment in step 5 include bronchial thermoplasty for some adults with severe asthma, anti-immunoglobulin E, sputum-guided treatment, add-on low-dose oral corticosteroids, and tiotropium. The document noted that evidence on bronchial thermoplasty is limited and long-term treatment effects are unknown (level of evidence B).

American College of Chest Physicians
In May 2014, the American College of Chest Physicians posted a position statement on coverage and payment for bronchial thermoplasty.16 The document stated in part: “...bronchial thermoplasty offers an important treatment option for adult patients with severe asthma who continue to be symptomatic despite maximal medical treatment and, therefore should not be considered experimental. Randomized controlled clinical trials of bronchial thermoplasty for severe asthma have shown a reduction in the rate of severe exacerbations, emergency department visits, and days lost from school or work. Additionally, data published in December 2013 demonstrates the persistence of the reduction in asthma symptoms achieved by bronchial thermoplasty for at least 5 years....”

National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (2018) published guidance on bronchial thermoplasty for severe asthma.17 The guidance stated: “Current evidence on the safety and efficacy on bronchial thermoplasty for severe asthma is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.” It was also noted that “further research should report details of patient selection and long-term safety and efficacy outcomes.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.
Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC002241265</td>
<td>Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma</td>
</tr>
<tr>
<td>NCT01832363a</td>
<td>Single-Session Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI</td>
</tr>
<tr>
<td>NCT02225392a</td>
<td>Unraveling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma (TASMA)</td>
</tr>
<tr>
<td>NCT02104856a</td>
<td>Bronchial Thermoplasty Global Registry (BT Registry)</td>
</tr>
<tr>
<td>NCT01185275</td>
<td>A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)</td>
</tr>
<tr>
<td>NCT02464995</td>
<td>Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations (THERMASCORT)</td>
</tr>
<tr>
<td>NCT03435237</td>
<td>Phenotyping Asthma for Bronchial Thermoplasty: Airway Smooth Muscle Structure and Function</td>
</tr>
<tr>
<td>NCT02975284</td>
<td>TASMA Extension Study: Long Term Efficacy and Safety of Bronchial Thermoplasty in Severe Asthma</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

a Denotes industry-sponsored or cosponsored trial.

References

3. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Bronchial thermoplasty for treatment of inadequately controlled severe asthma. TEC Assessments. 2014;Volume 29:Tab 12. PMID 25962190
7.01.127  Bronchial Thermoplasty

• No records required

### Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**IE**
The following services may be considered investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT®</strong></td>
<td>31660</td>
<td>Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe</td>
</tr>
<tr>
<td></td>
<td>31661</td>
<td>Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes</td>
</tr>
<tr>
<td><strong>HCPCS</strong></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td><strong>ICD-10</strong></td>
<td>0B538ZZ</td>
<td>Destruction of Right Main Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td></td>
<td>0B548ZZ</td>
<td>Destruction of Right Upper Lobe Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td></td>
<td>0B558ZZ</td>
<td>Destruction of Right Middle Lobe Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td></td>
<td>0B568ZZ</td>
<td>Destruction of Right Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
</tbody>
</table>
### Types of Bronchial Thermoplasty

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destruction</td>
<td>0B578ZZ</td>
<td>Of Left Main Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td>Destruction</td>
<td>0B588ZZ</td>
<td>Of Left Upper Lobe Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td>Destruction</td>
<td>0B598ZZ</td>
<td>Of Lingula Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
<tr>
<td>Destruction</td>
<td>0B5B8ZZ</td>
<td>Of Left Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic</td>
</tr>
</tbody>
</table>

### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/06/2012</td>
<td>BCBSA Medical Policy adoption</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/13/2012</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>02/22/2013</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>11/26/2014</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>08/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>08/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>08/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>09/01/2019</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.
Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.